Farxiga findings highlight potential for earlier use of SGLT-2 inhibitors

AstraZeneca (LSE: AZN) has presented new data at the American Diabetes Association’s 77th Scientific Sessions underpinning the safety profile of its type 2 diabetes drug Farxiga (dapagliflozin).

The Anglo-Swedish pharma major has presented an analysis of data pooled from dapagliflozin clinical trials, as well as three new cardiovascular (CV) outcomes analyses from the ongoing CVD-REAL study, the first large real-world evidence study of its kind evaluating treatment with SGLT-2 inhibitors (SGLT-2i), including dapagliflozin.

In an updated safety analysis, data pooled from 30 Phase IIb/III clinical trials for dapagliflozin showed no new safety signals and the incidence of adverse events was generally similar to that in the control groups.